Contradictions Unveiled: Theravance Biopharma's 2025Q2 Earnings Call Highlights Pricing, Strategy, and Market Dynamics

Pricing strategy for Ampreloxetine, YUPELRI channel strategy and performance, YUPELRI international expansion strategy, SG&A expense and commercialization strategy for Ampreloxetine, YUPELRI prescribing patterns and ensifentrine impact are the key contradictions discussed in Theravance Biopharma's latest 2025Q2 earnings call.



Commercial Success of YUPELRI:
- YUPELRI's net sales reached approximately $66 million in Q2, driven by continued demand growth and favorable net pricing, with strong pull-through performance in the hospital channel.
- The growth was supported by a shift in channel mix, with increasing demand through specialty pharmacy, which improves patient fulfillment and persistency.

Strategic Transactions and Financial Strength:
- Theravance Biopharma completed the $225 million sale of its remaining royalty interest in TRELEGY to GSK, strengthening its financial position.
- This transaction is expected to trigger the remaining $150 million in milestones from Royalty Pharma over the next 18 months, further enhancing Theravance's financial outlook.

Ampreloxetine Development Progress:
- The Phase III CYPRESS trial for ampreloxetine is on track to complete enrollment in the open-label portion over the next few weeks, with expected top-line data approximately six months later.
- The trial's design, focusing on a specific MSA subgroup and leveraging a randomized withdrawal endpoint, is anticipated to provide meaningful insights into the therapeutic benefits of ampreloxetine.

Market Opportunity and Payer Engagement for Ampreloxetine:
- Theravance estimates an addressable population of approximately 40,000 patients in the U.S. for ampreloxetine, indicating a significant market opportunity.
- The company is actively engaging payers, emphasizing the high unmet need and value proposition of the drug to position ampreloxetine effectively upon market approval.